These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29548481)

  • 1. p16(INK4a) status and survival benefit of EGFR inhibitors in head and neck squamous cell cancer: A systematic review and meta-analysis.
    Su Y; Cui J; Xu D; Wang M; Xu T; Tian H; Han F
    Crit Rev Oncol Hematol; 2018 Apr; 124():11-20. PubMed ID: 29548481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma.
    Young RJ; Rischin D; Fisher R; McArthur GA; Fox SB; Peters LJ; Corry J; Lim A; Waldeck K; Solomon B
    Cancer Epidemiol Biomarkers Prev; 2011 Jun; 20(6):1230-7. PubMed ID: 21467228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation.
    Baschnagel AM; Williams L; Hanna A; Chen PY; Krauss DJ; Pruetz BL; Akervall J; Wilson GD
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):701-7. PubMed ID: 24521684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.
    Cohen EEW; Licitra LF; Burtness B; Fayette J; Gauler T; Clement PM; Grau JJ; Del Campo JM; Mailliez A; Haddad RI; Vermorken JB; Tahara M; Guigay J; Geoffrois L; Merlano MC; Dupuis N; Krämer N; Cong XJ; Gibson N; Solca F; Ehrnrooth E; Machiels JH
    Ann Oncol; 2017 Oct; 28(10):2526-2532. PubMed ID: 28961833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of age on the overall survival benefits of anti-EGFR-containing regimens in head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials.
    Zhao Y; Liu W; Sun M; Miao Q; Liu Y; Tian H; Su Y; Han F
    Crit Rev Oncol Hematol; 2019 Mar; 135():39-46. PubMed ID: 30819445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis.
    Zhang S; Chen J; Jiang H; Ma H; Yang B
    Eur J Clin Pharmacol; 2012 May; 68(5):561-9. PubMed ID: 22231637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of p16 expression, nodal status, and smoking on oncologic outcomes of patients with head and neck unknown primary squamous cell carcinoma.
    Dixon PR; Au M; Hosni A; Perez-Ordonez B; Weinreb I; Xu W; Song Y; Huang SH; O'Sullivan B; Goldstein DP; de Almeida JR
    Head Neck; 2016 Sep; 38(9):1347-53. PubMed ID: 27002481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The primary site of head and neck squamous cell carcinoma predicts survival benefits of EGFR inhibitors: A systematic review and meta-analysis.
    Nie D; Wang X; Sun M; Feng Z; Pei F; Liu W; Wang Z; Han F
    Radiother Oncol; 2021 May; 158():13-20. PubMed ID: 33587969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer.
    Pajares B; Trigo JM; Toledo MD; Álvarez M; González-Hermoso C; Rueda A; Medina JA; de Luque V; Jerez JM; Alba E
    BMC Cancer; 2013 Jan; 13():26. PubMed ID: 23331666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different cellular p16(INK4a) localisation may signal different survival outcomes in head and neck cancer.
    Zhao N; Ang MK; Yin XY; Patel MR; Fritchie K; Thorne L; Muldrew KL; Hayward MC; Sun W; Wilkerson MD; Chera BS; Hackman T; Zanation AM; Grilley-Olson JE; Couch ME; Shockley WW; Weissler MC; Shores CG; Funkhouser WK; Olshan AF; Hayes DN
    Br J Cancer; 2012 Jul; 107(3):482-90. PubMed ID: 22735904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
    Kim HS; Kwon HJ; Jung I; Yun MR; Ahn MJ; Kang BW; Sun JM; Kim SB; Yoon DH; Park KU; Lee SH; Koh YW; Kim SH; Choi EC; Koo DH; Sohn JH; Kim B; Kwon NJ; Yun HJ; Lee MG; Lee JH; Kim TM; Kim HR; Kim JH; Paik S; Cho BC
    Clin Cancer Res; 2015 Feb; 21(3):544-52. PubMed ID: 25424851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck.
    Lassen P; Eriksen JG; Hamilton-Dutoit S; Tramm T; Alsner J; Overgaard J
    J Clin Oncol; 2009 Apr; 27(12):1992-8. PubMed ID: 19289615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
    Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
    Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):50-61. PubMed ID: 26454839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-EGFR-targeting agents in recurrent or metastatic head and neck carcinoma: a meta-analysis.
    Petrelli F; Barni S
    Head Neck; 2012 Nov; 34(11):1657-64. PubMed ID: 21953841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
    Machiels JP; Schmitz S
    Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma.
    Qian G; Jiang N; Wang D; Newman S; Kim S; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR; Chen ZG; Saba NF
    Cancer; 2015 Oct; 121(20):3600-11. PubMed ID: 26195293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.
    Massarelli E; Lin H; Ginsberg LE; Tran HT; Lee JJ; Canales JR; Williams MD; Blumenschein GR; Lu C; Heymach JV; Kies MS; Papadimitrakopoulou V
    Ann Oncol; 2015 Jul; 26(7):1476-80. PubMed ID: 26025965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor biology in head and neck cancer.
    Kalyankrishna S; Grandis JR
    J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.